• Clinical and Experimental Pediatrics
• /
• 제50권4호
• /
• pp.355-362
• /
• 2007

목 적 : 3가 항원 DTaP 백신을 3회 기초 접종 받은 건강한 국내 영아에서 면역원성 및 안전성을 평가하고자 하였다. 방 법 : 2004년 4월부터 2005년 4월까지 5개 연구 참여 대학병원에서 제태기간 32주 이상에서 태어난 건강한 영아에게 생후 2, 4, 6개월에 3가 항원 DTaP 백신($Infanrix^{(R)}$)을 대퇴부 전외측에 접종하여 접종 전 혈청과 3차 접종 1개월 후 혈청에서 디프테리아, 파상풍, PT, FHA, PRN 항원에 대한 항체를 측정하여 면역원성을 평가하였고, 접종 후 3일 내에 발생이 예상되는 국소 및 전신 이상반응을 적극 관찰하였고 3주내에 발생한 모든 이상반응을 관찰하여 안전성 평가를 실시하였다. 한편, 2가 항원 DTaP 백신을 접종 받은 14명을 대조군으로 설정하여 연구군과 동일한 방법으로 면역원성을 평가하여 비교하였다. 결 과 : 60명에서 실시된 연구군의 면역원성 평가에서 디프테리아, 파상풍, FHA, PRN 항원에 대한 항체 양전율은 100%이었고, PT 항원에 대한 항체 양전율은 98.3%이었다. 한편 대조군에서 디프테리아, 파상풍, PT, FHA 항원에 대한 항체 양전율은 100%이었으나 PRN 항원에 대한 항체 양전율은 50%이었다. 147명에서 확인된 이상반응 평가에서 연구 기간동안 연구 백신과 인과관계가 있는 중증 이상반응은 없었고, 3일 내에 특이한 치료 및 처치가 없이 자연 소멸되는 국소 및 전신 이상반응만 관찰되었으며 접종 차수별 이상반응의 증가도 없었다. 결 론 : 이상의 결과를 볼 때에 3가 항원 DTaP 백신($Infanrix^{(R)}$)은 국내 영아 기초 접종에 유효한 백신임을 확인할 수 있었고, 국내에서 가장 많이 사용되고 있는 2가 DTaP 백신에 비해 PRN항원에 대한 항체의 면역원성이 높은 이점이 있음을 확인하였다. 그러나 향후 더욱 많은 대상을 통한 연구가 이루어져 이런 결과를 재입증하여야 할 것이고, 추가 접종에 대한 동일한 연구도 요구된다.

• 대한수의학회지
• /
• 제26권1호
• /
• pp.103-108
• /
• 1986

The oil emulsion and alhydrogel pilli vaccines were prepared from a strain(O9: K35, K99, F41) of enterotoxigenic Escherichia coli isolated from calves with diarrhea and their immunogenicity was tested in guinea-pigs, pregnant goats and cows. Serum antibody responses to K99 and F41 antigens in guinea-pigs given experimental oil and gel vaccines peaked at 4 and 6 weeks after vaccinations. At that time, the mean hemagglutination inhibition titers to K99 and F41 antigens in guinea-pigs given oil vaccine were 1:25 and 1:1, 218 and those given gel vaccine were 1:54 and 1:724 respectively. Agglutinin titers in pregnant goats given the oil vaccine were significantly higher(mean 1:2,347) compared to those of control group(mean 1:160). Less than 12.5% of goatlings from vaccinated goats developed scours compared to nearly 100% in control group after oral challenge with enterotoxigenic Escherichia coil within 24 hours after birth. The highest agglutinin titers of cow serum and colostrum and of the serum of calves 48 hours after birth from cows given oil vaccine were 1:256, 1:512 and 1:64 respectively. On the other hand, those titers of serum and colostrum and of the serum of nursing calves from nonvaccinated cows were 1:8, 1:16 and 1:20 respectively. The protective efficacy of the oil emulsion vaccine was 72.1% under field conditions. These results strongly indicated that the vaccine could be applied for protection of diarrhea caused by enterotoxigenic Escherichia coli in calves.

• 한국미생물학회:학술대회논문집
• /
• 한국미생물학회 2009년도 International Meeting of the Microbiological Society of Korea
• /
• pp.72-73
• /
• 2009

• 대한수의학회지
• /
• 제35권4호
• /
• pp.753-758
• /
• 1995

The study was carried out to investigate the pathogenicity of EHV isolate to hamsters and mice and immunogenicity of experimentally produced. vaccine were evaluated in the horses. Hamsters infected. intranasally with $LC_1$ isolate showed symptoms of nasal discharge, conjunctivitis and body weight loss during the observation period of 12 days after infection, while only slight depression and body weight loss were noticed with mice infected with $LC_1$ indicating that hamsters are more susceptible to the virus. Antibody titer of mice and hamsters were gradually increased to highest level of 1:2560~10240, 1:640~1280, respectively, at 7~12 days post vaccination. Horses immunized against $LC_1$ killed vaccine reached to maximum antibody titer of 1:20480 around 4 weeks after 1st vaccination and declined after 12 weeks post vaccination. No significant antibody increase were detected after 2nd vaccination. Mean body temperature and mean total leukocyte counts remained within normal range and no adverse reaction were noticed after vaccination.

• 대한수의학회지
• /
• 제47권1호
• /
• pp.59-65
• /
• 2007

Pasteurella multocida Pasteurella multocida toxin (PMT) is a causal pathogenin atrophic rhinitis in pigs. To investigate the protective immunity and vaccination effect of recombinantPMT, the gene for PMT was isolated from the infective P. multocida D:4. The 2.3 kb XhoI/PstI fragment(PMT2.3) of PMT gene was expressed in E. coli BL21 (DE3) using the induced expression vector system.The recombinant protein of PMT2.3 having molecular weight of 84 kDa was purified by Ni-afinitycolumn chromatography. The PMT2.3 raised slightly less anti-PMT antibody titer than formalin-killedwhole cel, however, it showed more protective imunity against P. multocida D:4 infection in vaccinationand chalenge.

• Pediatric Infection and Vaccine
• /
• 제4권2호
• /
• pp.257-264
• /
• 1997

목 적 : 국내 건강한 소아에서의 47계대 배양된 Oka주 수두 약독화 생백신의 단기간내 체액성 면역원성과 안전성 평가를 위해 본 연구를 시행하였다. 대상 및 방법 : 1997년 4월부터 1997년 8월까지 5개월간 가톨릭대학부속 성모자애병원 육아상담실을 방문한 소아와, 서울, 인천, 수원 지역에 있는 4곳의 보육원에 수용되고 있는 원아들 중 과거력상 수두에 이환되지 않았고, 수두백신 접종력이 없으며 중한 기저질환이나 약제 및 백신에 알레르기가 없는 12개월에서 15세 사이 연령의 건강한 소아를 대상으로 하였다. 백신의 접종은 1,400 PFU 용량의 47 계대 Oka주 수두백신을 상완 삼각근에 1회 피하 주사하였다. 단기간(접종후 6주)의 체액성 면역원성을 평가하기 위해 모든 피접종아에서 접종전, 접종 6주 후에 채혈하여 FAMA 법과 효소 면역법으로 수두 대상포진 바이러스의 세포막 항체와 IgG를 측정 비교하였다. 그리고 안전성 평가를 위해 접종 30분내 즉각반응, 접종 3일내 국소 및 전신반응, 접종 6주후까지의 백신에 의한 전신성 부작용 발생을 관찰하였다. 결과 : 1) 총 99명의 소아에서 접종과 검사가 완료되었다{육아상담실; 33명, 보육원 66명). 이들 중 49명은 접종전 대상포진 바이러스 항체 검사상 음성이었고 50명은 양성으로 판명되었다. 이 두군의 연령 및 성별분포는 유사하였다. 2) FAMA 법으로 시행한 검사상 접종전 음성군에서 97.9%의 양전율을 보였고, 음성군 및 양성군 모두에서 의의있는 GMT 상승을 보였다. 3) 효소 면역법으로 시행한 결과에서는 접종전 음성군에서는 100%의 항체 양전율을 보였고, 그리고 양성군에서도 항체가는 접종후 유의하게 상승하였다. 4) 경한 주사부위의 발적, 동통, 부종, 경결 등의 국소반응과 보챔, 식욕부진 등의 전신반응이 있었으나 3일내에 소실되었고, 이후 6주간 백신에 의한 부작용은 전례에서 관찰되지 않았다. 결 론 : 이상의 결과로 볼 때에 47계대 배양된 Oka주 수두백신은 단기간내에 높은 체액성 면역원성이 유발되고 안전성이 있음을 알 수 있었다. 그러나 이 백신의 광범위한 사용을 위해서는 지속적으로 장기간의 체액성 및 세포 매개성 면역원성 검증과 야외임상 대조설험 등이 요구되어 진다.

• 한국식물생명공학회:학술대회논문집
• /
• 한국식물생명공학회 2003년도 식물바이오벤처 페스티발
• /
• pp.169-169
• /
• 2003

• Journal of Microbiology and Biotechnology
• /
• 제27권8호
• /
• pp.1539-1548
• /
• 2017

Pseudomonas aeruginosa (P. aeruginosa) is an opportunistic pathogen that commonly causes fatal infections in cystic fibrosis and burn patients as well as in patients who are hospitalized or have impaired immune systems. P. aeruginosa infections are difficult to treat owing to the high resistance of the pathogen to conventional antibiotics. Despite several efforts, no effective prophylactic vaccines against P. aeruginosa are currently available. In this study, we investigated the activity of the CIA06 adjuvant system, which is composed of alum and de-O-acylated lipooligosaccharide, on a P. aeruginosa outer membrane protein (OMP) antigen vaccine in mice. The results indicated that CIA06 significantly increased the antigen-specific IgG titers and opsonophagocytic activity of immune sera against P. aeruginosa. In addition, the antibodies induced by the CIA06-adjuvanted vaccine exhibited higher cross-reactivity with heterologous P. aeruginosa strains. Finally, mice immunized with the CIA06-adjuvanted vaccine were effectively protected from lethal P. aeruginosa challenge. Based on these data, we suggest that the CIA06 adjuvant system might be used to promote the immunogenicity and protective efficacy of the P. aeruginosa OMP vaccine.

• Parasites, Hosts and Diseases
• /
• 제51권2호
• /
• pp.147-154
• /
• 2013

To control coccidiosis without using prophylactic medications, a DNA vaccine targeting the gametophyte antigen Gam56 from Eimeria maxima in chickens was constructed, and the immunogenicity and protective effects were evaluated. The ORF of Gam56 gene was cloned into an eukaryotic expression vector pcDNA3.1(zeo)+. Expression of Gam56 protein in COS-7 cells transfected with recombinant plasmid pcDNA-Gam56 was confirmed by indirect immunofluorescence assay. The DNA vaccine was injected intramuscularly to yellow feathered broilers of 1-week old at 3 dosages (25, 50, and $100{\mu}g/chick$). Injection was repeated once 1 week later. One week after the second injection, birds were challenged orally with $5{\times}10^4$ sporulated oocysts of E. maxima, then weighed and killed at day 8 post challenge. Blood samples were collected and examined for specific peripheral blood lymphocyte proliferation activity and serum antibody levels. Compared with control groups, the administration of pcDNA-Gam56 vaccine markedly increased the lymphocyte proliferation activity (P<0.05) at day 7 and 14 after the first immunization. The level of lymphocyte proliferation started to decrease on day 21 after the first immunization. A similar trend was seen in specific antibody levels. Among the 3 pcDNA-Gam56 immunized groups, the median dosage group displayed the highest lymphocyte proliferation and antibody levels (P<0.05). The median dosage group had the greatest relative body weight gain (89.7%), and the greatest oocyst shedding reduction (53.7%). These results indicate that median dosage of DNA vaccine had good immunogenicity and immune protection effects, and may be used in field applications for coccidiosis control.

• 대한수의학회지
• /
• 제63권1호
• /
• pp.5.1-5.9
• /
• 2023

Feline panleukopenia virus (FPV), feline calicivirus (FCV), and feline herpesvirus type-1 (FHV-1) are major infectious pathogens in cats. We evaluated the immunogenicity of a new vaccine containing inactivated FPV, two FCVs, and FHV-1 in animals. An FPV, two FCVs, and an FHV-1 isolate were continuously passaged 70, 50, 80, and 100 times in CRFK cells. FP70, FC50, FC80, and FH100 were propagated and used as vaccine antigens. Two inactivated feline virus vaccines, feline rehydragel-adjuvanted vaccine (FRAV) and feline cabopol-adjuvanted vaccine (FCAV) were prepared and inoculated into mice and guinea pigs. Humoral immune responses were measured using hemagglutination inhibition (HI) for FPV and virus-neutralizing antibody (VNA) for two FCVs and FHV-1 tests. Serial passages in CRFK cells resulted in increase in titers of FPV and two FCVs but not FHV-1 The FCAV induced higher mean HI and VNA titers than the FRAV in guinea pigs; therefore, the FCAV was selected. Cats inoculated with FCAV developed a mean HI titer of 259.9 against FPV, and VNA titers of 64, 256, and 3.2 against FCV17D03, FCV17D283, and FHV191071, respectively. Therefore, cats inoculated with the FCAV showed a considerable immune response after receiving a booster vaccination.